Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda Minima

June 2020 in “ Processes ”

Byoung Ha Kim, Won-Yung Lee, Tuy An Trinh, Jae Sung Pyo, Sooyeun Lee, Chang-Eop Kim, Dong Hwan Lee, Eun‐Seok Park, Ki Sung Kang

brevilin A JAK3 inhibitor Centipeda minima CMX JAK-STAT signaling pathway cytokine–cytokine receptor interactions MAPK signaling pathway vertex balding

Studysummary This study suggests that the emulsion extract of brevilin A from Centipeda minima may stimulate hair regrowth in individuals with mild to moderate vertex balding by inhibiting JAK3. Our plain-language summary of this paper — not a Tressless recommendation.

The study assessed the hair regrowth effects of CMX, an emulsion extract containing brevilin A from Centipeda minima, a JAK3 inhibitor, in a clinical trial with 72 patients experiencing mild to moderate hair loss. Over 24 weeks, the CMX-treated group showed significant improvements in total, terminal, and anagen hair counts compared to the placebo group, with statistical significance (p < 0.001). The effectiveness of CMX was linked to its modulation of the JAK-STAT signaling pathway and related pathways, suggesting its potential as a promising treatment for hair loss with fewer side effects than traditional drugs.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

10 / 10 results

research The Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata: A Systematic Review

19 citations , August 2019 in “Dermatologic therapy”

This review discusses the use of Janus kinase inhibitors for alopecia areata and reports promising short-term efficacy but low-quality evidence, highlighting the need for further research to confirm long-term safety and effectiveness.

research Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata

11 citations , June 2019 in “Journal of dermatology”

This source reports that recent research highlights the effectiveness and tolerability of oral JAK inhibitors for treating moderate to severe alopecia areata, although further placebo-controlled studies are needed to confirm their long-term safety and efficacy.

research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature

17 citations , January 2019 in “Journal of cutaneous medicine and surgery”

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

research Emerging Drugs for Alopecia Areata: JAK Inhibitors

20 citations , January 2018 in “Expert opinion on emerging drugs”

This review discusses the potential of Janus Kinase inhibitors for treating alopecia areata and other forms of alopecia, highlighting the need for further research on their long-term safety and optimal formulation.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Overview of Alopecia Areata

110 citations , December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.

Alopecia Areata: An Autoimmune Disease Causing Hair Loss